Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases

Chest

Volumn 123, Issue 1, 2003, Pages 261-265

  Garey, Kevin W ^a,d   Alwani, Anita ^b,d   Danziger, Larry H ^c,d   Rubinstein, Israel ^b,c,d  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Anti inflammatory; Immunomodulatory; Macrolide antibiotics

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; ROXITHROMYCIN; TROLEANDOMYCIN;

ADJUVANT CHEMOTHERAPY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHIECTASIS; BRONCHIOLITIS; CHRONIC BRONCHITIS; CYSTIC FIBROSIS; DRUG EFFECT; GRAM NEGATIVE INFECTION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LUNG DISEASE; NOSE POLYP; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFLAMMATION; REVIEW; RHINOSINUSITIS; TISSUE REPAIR;

EID: 0037252366     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.123.1.261     Document Type: Review

References (68)

1. Garey KW, Amsden GW. Intravenous azithromycin. Ann Pharmacother 1999; 33:218-228
2. Charles L, Segreti J. Choosing the right macrolide antibiotic: a guide to selection. Drugs 1997; 53:349-357
3. Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc 1999; 74:613-634
4. Labro MT. Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother 1998; 41(Suppl B):37-46
5. Labro MT. Immunomodulation by antibacterial agents: is it clinically relevant? Drugs 1993; 45:319-328
6. Sakito O, Kadota J, Kohno S, et al. Interleukin 1β, tumor necrosis factor α, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63:42-48
7. Nagai H, Shishido H, Yoneda R, et al. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991; 58:145-149
8. Hashiba M, Baba S. Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol Suppl 1996; 525:73-78
9. Jaffe A, Francis J, Rosenthal M, et al. Long-term azithromycin may improve lung function in children with cystic fibrosis [letter]. Lancet 1998; 351:420
10. Garey KW, Rubinstein I, Gotfried MH, et al. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 2000; 118:1826-1827
11. Labro MT, el Benna J. Effects of anti-infectious agents on polymorphonuclear neutrophils. Eur J Clin Microbiol Infect Dis 1991; 10:124-131
12. Miyachi Y, Yoshioka A, Imamura S, et al. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol 1986; 86:449-453
13. Van Bambeke F, Montenez JP, Piret J, et al. Interaction of the macrolide azithromycin with phospholipids: I. Inhibition of lysosomal phospholipase A1 activity. Eur J Pharmacol 1996; 314:203-214
14. Feldman C, Anderson R, Theron AJ, et al. Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro. Inflammation 1997; 21:655-665
15. Anderson R, Theron AJ, Feldman C. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation 1996; 20:693-705
16. Hamilos DL. Chronic sinusitis. J Allergy Clin Immunol 2000; 106:213-227
17. Bachert C, Van Cauwenberge PB. Inflammatory mechanisms in chronic sinusitis. Acta Otorhinolaryngol Belg 1997; 51:209-217
18. Majima Y, Masuda S, Sakakura Y. Quantitative study of nasal secretory cells in normal subjects and patients with chronic sinusitis. Laryngoscope 1997; 107(pt 1):1515-1518
19. Suzuki H, Shimomura A, Ikeda K, et al. Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. Tohoku J Exp Med 1997; 182:115-124
20. Suzuki H, Asada Y, Ikeda K, et al. Inhibitory effect of erythromycin on interleukin-8 secretion from exudative cells in the nasal discharge of patients with chronic sinusitis. Laryngoscope 1999; 109:407-410
21. Suzuki H, Ikeda K, Honma R, et al. Prognostic factors of chronic rhinosinusitis under long-term low-dose macrolide therapy. ORL J Otorhinolaryngol Relat Spec 2000; 62:121-127
22. Suzuki H, Takahashi Y, Wataya H, et al. Mechanism of neutrophil recruitment induced by IL-8 in chronic sinusitis. J Allergy Clin Immunol 1996; 98:659-670
23. Rhee CS, Majima Y, Arima S, et al. Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. Ann Otol Rhinol Laryngol 2000; 109:484-487
24. Oishi K, Sonoda F, Kobayashi S, et al. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun 1994; 62:4145-4152
25. Cazzola M, Salzillo A, Diamare F. Potential role of macrolides in the treatment of asthma. Monaldi Arch Chest Dis 2000; 55:231-236
26. Itkin IH, Menzel ML. The use of macrolide antibiotic substances in the treatment of asthma. J Allergy 1970; 45:146-162
27. Zeiger RS, Schatz M, Sperling W, et al. Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma. J Allergy Clin Immunol 1980; 66:438-446
28. Spector S, Katz F, Farr R. Troleandomycin: effectiveness in steroid-dependent asthma and bronchitis. J Allergy Clin Immunol 1974; 54:367-379
29. Weinberger M, Hudgel D, Spector S, et al. Inhibition of theophylline clearance by troleandomycin. J Allergy Clin Immunol 1977; 59:228-231
30. Weinberger M. TAO and theophylline [letter]. Hosp Pract 1978; 13:22
31. Andrade WP, Renard RL, Nelson HS. The effect of troleandomycin and methylprednisolone alone and in combination on bronchial sensitivity to methacholine. Ann Allergy 1983; 51:515-517
32. Eitches RW, Rachelefsky GS, Katz RM, et al. Methylprednisolone and troleandomycin in treatment of steroid-dependent asthmatic children. Am J Dis Child 1985; 139:264-268
33. Black PN. Anti-inflammatory effects of macrolide antibiotics. Eur Respir J 1997; 10:971-972
34. Flotte TR, Loughlin GM. Benefits and complications of troleandomycin (TAO) in young children with steroid-dependent asthma. Pediatr Pulmonol 1991; 10:178-182
35. Rosenberg SM, Gerhard H, Grunstein MM, et al. Use of TAO without methylprednisolone in the treatment of severe asthma. Chest 1991; 100:849-850
36. Gotfried MH Jr, Messick C, Rubinstein IR, et al. Placebo controlled trial evaluating the efficacy of clarithromycin in subjects with corticosteroid-dependent asthma. Birmingham, UK: 21st International Congress of Chemotherapy, 1999
37. Wynn SR. Mast cell stabilizers, anticholinergics, corticosteroids, and troleandomycin. J Allergy Clin Immunol 1989; 84(pt 2):1100-1103
38. Miyatake H, Taki F, Taniguchi H, et al. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest 1991; 99:670-673
39. Miyatake H, Suzuki K, Taki F, et al. Effect of erythromycin on bronchial hyperresponsiveness in patients with bronchial asthma. Arzneimittelforschung. 1991; 41:552-556
40. Hendeles L. Erythromycin for the treatment of bronchial hyperresponsiveness in asthma [letter]. Chest 1992; 101:296
41. Kamoi H, Kurihara N, Fujiwara H, et al. The macrolide antibacterial roxithromycin reduces bronchial hyperresponsiveness and superoxide anion production by polymorphonuclear leukocytes in patients with asthma. J Asthma 1995; 32:191-197
42. Shimizu T, Kato M, Mochizuki H, et al. Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma. Chest 1994; 106:458-461
43. Tamaoki J, Tagaya E, Sakai A, et al. Effects of macrolide antibiotics on neurally mediated contraction of human isolated bronchus. J Allergy Clin Immunol 1995; 95:853-859
44. Hahn DL. Chlamydia pneumoniae and asthma. Thorax 1998; 53:1095-1096
45. Hahn DL. Chlamydia pneumoniae, asthma, and COPD: what is the evidence? Ann Allergy Asthma Immunol 1999; 83:271-288
46. Sugiyama Y. Diffuse panbronchiolitis. Clin Chest Med 1993; 14:765-772
47. Kudoh S. Erythromycin treatment in diffuse panbronchiolitis. Curr Opin Pulm Med 1998; 4:116-121
48. Koyama H, Geddes DM. Erythromycin and diffuse panbronchiolitis. Thorax 1997; 52:915-918
49. Inamura K, Ohta N, Fukase S, et al. The effects of erythromycin on human peripheral neutrophil apoptosis. Rhinology 2000; 38:124-129
50. Ogushi F, Tani K, Maniwa K, et al. Interleukin-8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis or idiopathic pulmonary fibrosis. J Med Invest 1997; 44:53-58
51. Katsuki M. Neutrophil chemotactic activity in bronchoalveolar lavage fluid recovered from patients with diffuse panbronchiolitis. Kurume Med J 1996; 43:279-287
52. Fujii T, Kadota J, Kawakami K, et al. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995; 50:1246-1252
53. Mysliwiec V, Pina JS. Bronchiectasis: the "other" obstructive lung disease. Postgrad Med 1999; 106:123-126,128-131
54. Hansell DM. Bronchiectasis. Radiol Clin North Am 1998; 36:107-128
55. Kolbe J, Wells AU. Bronchiectasis: a neglected cause of respiratory morbidity and mortality. Respirology 1996; 1:221-225
56. Tsang KW, Ho PI, Chan KN, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999; 13:361-364
57. Koh YY, Lee MH, Sun YH, et al. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997; 10: 994-999
58. Nakamura H, Fujishima S, Inoue T, et al. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J 1999; 13: 1371-1379
59. Dinwiddie R. Pathogenesis of lung disease in cystic fibrosis. Respiration 2000; 67:3-8
60. Denton M, Wilcox MH. Antimicrobial treatment of pulmonary colonization and infection by Pseudomonas aeruginosa in cystic fibrosis patients. J Antimicrob Chemother 1997; 40: 468-474
61. Doring G. Cystic fibrosis respiratory infections: interactions between bacteria and host defence. Monaldi Arch Chest Dis 1997; 52:363-366
62. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996; 60:539-574
63. Boyd A, Chakrabarty AM. Pseudomonas aeruginosa biofilms: role of the alginate exopolysaccharide. J Ind Microbiol 1995; 15:162-168
64. May TB, Chakrabarty AM. Pseudomonas aeruginosa: genes and enzymes of alginate synthesis. Trends Microbiol 1994; 2:151-157
65. Howe RA, Spencer RC. Macrolides for the treatment of Pseudomonas aeruginosa infections? J Antimicrob Chemother. 1997; 40:153-155
66. Kita E, Sawaki M, Oku D, et al. Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin. J Antimicrob Chemother 1991; 27:273-284
67. Majtan V, Hybenova D. Inhibition of Pseudomonas aeruginosa alginate expression by subinhibitory concentrations of antibiotics. Folia Microbiol (Praha) 1996; 41:61-64
68. Hotta M. Neutrophil chemotactic activity in cryptogenic organizing pneumonia and the response to erythromycin. Kurume Med J 1996; 43:207-217